Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 836826 + GemOx vs R-GemOx in R/R DLBCL
NCT02624492Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2016
- Primary completion
- Mar 2018
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of BI 836826 in diffuse large B-cell lymphoma (DLBCL), sponsored by Boehringer Ingelheim. Started Jan 2016; status: completed.
02
Drugs
BI 836826
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT02624492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02624492.